- Eli Lilly ( NYSE: LLY ) announced a modified purchase agreement with the U.S. government on Wednesday to deliver an extra 150,000 doses of its COVID-19 antibody therapy, bebtelovimab for approximately $275M.
- The supplies are expected begin immediately and complete on or before Aug. 05, the company said, projecting nearly $275M revenue and $0.08 earnings per share impact from the deal for 2022 financials.
- The agreement includes a provision to deliver additional 350,000 doses subject to an option exercise expected on or before Sep. 14.
- Bebtelovimab is a monoclonal antibody discovered by AbCellera Biologics ( ABCL ) which later licensed it to Lilly ( LLY ) for further development.
For further details see:
Lilly to supply additional 150K doses of COVID-19 antibody therapy to U.S.